TY - JOUR AU - Cookson, M. S. AU - Roth, B. J. AU - Dahm, P. PY - 2013 DA - 2013// TI - Castration-resistant prostate Cancer: AUA guideline JO - J Urol VL - 190 ID - Cookson2013 ER - TY - JOUR AU - Halabi, S. AU - Kelly, W. K. AU - Ma, H. PY - 2016 DA - 2016// TI - Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate Cancer JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology VL - 34 ID - Halabi2016 ER - TY - JOUR AU - Xie, W. AU - Regan, M. M. AU - Buyse, M. PY - 2017 DA - 2017// TI - Metastasis-free survival is a strong surrogate of overall survival in localized prostate Cancer JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology. VL - 35 ID - Xie2017 ER - TY - JOUR AU - Smith, M. R. AU - Kabbinavar, F. AU - Saad, F. PY - 2005 DA - 2005// TI - Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate Cancer JO - J Clin Oncol VL - 23 ID - Smith2005 ER - TY - JOUR AU - Alpajaro, S. I. R. AU - Harris, J. A. K. AU - Evans, C. P. PY - 2019 DA - 2019// TI - Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies JO - Prostate Cancer Prostatic Dis VL - 22 ID - Alpajaro2019 ER - TY - JOUR AU - Patel, M. I. AU - DeConcini, D. T. AU - Lopez-Corona, E. AU - Ohori, M. AU - Wheeler, T. AU - Scardino, P. T. PY - 2004 DA - 2004// TI - An analysis of men with clinically localized prostate cancer who deferred definitive therapy JO - J Urol VL - 171 ID - Patel2004 ER - TY - JOUR AU - Latini, D. M. AU - Hart, S. L. AU - Knight, S. J. PY - 2007 DA - 2007// TI - The relationship between anxiety and time to treatment for patients with prostate Cancer on surveillance JO - J Urol VL - 178 ID - Latini2007 ER - TY - JOUR AU - Fizazi, K. AU - Shore, N. AU - Tammela, T. L. PY - 2019 DA - 2019// TI - Darolutamide in nonmetastatic, castration-resistant prostate Cancer JO - N Engl J Med VL - 380 ID - Fizazi2019 ER - TY - JOUR AU - Hussain, M. AU - Fizazi, K. AU - Saad, F. PY - 2018 DA - 2018// TI - Enzalutamide in men with nonmetastatic, castration-resistant prostate Cancer JO - N Engl J Med VL - 378 ID - Hussain2018 ER - TY - JOUR AU - Smith, M. R. AU - Saad, F. AU - Chowdhury, S. PY - 2018 DA - 2018// TI - Apalutamide treatment and metastasis-free survival in prostate Cancer JO - N Engl J Med VL - 378 ID - Smith2018 ER - TY - JOUR AU - Bekker-Grob, E. W. AU - Bliemer, M. C. AU - Donkers, B. PY - 2013 DA - 2013// TI - Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment JO - Br J Cancer VL - 109 ID - Bekker-Grob2013 ER - TY - JOUR AU - King, M. T. AU - Viney, R. AU - Smith, D. P. PY - 2012 DA - 2012// TI - Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer JO - Br J Cancer VL - 106 ID - King2012 ER - TY - STD TI - Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ (Clinical research ed). 2004;328(7436):382. ID - ref13 ER - TY - JOUR AU - Lloyd, A. AU - Penson, D. AU - Dewilde, S. AU - Kleinman, L. PY - 2008 DA - 2008// TI - Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer JO - Prostate Cancer Prostatic Dis VL - 11 ID - Lloyd2008 ER - TY - JOUR AU - Uemura, H. AU - Matsubara, N. AU - Kimura, G. PY - 2016 DA - 2016// TI - Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment JO - BMC Urol VL - 16 ID - Uemura2016 ER - TY - JOUR AU - Eliasson, L. AU - Freitas, H. M. AU - Dearden, L. AU - Calimlim, B. AU - Lloyd, A. J. PY - 2017 DA - 2017// TI - Patients’ preferences for the treatment of metastatic castrate-resistant prostate Cancer: a discrete choice experiment JO - Clin Ther VL - 39 ID - Eliasson2017 ER - TY - JOUR AU - Hauber, A. B. AU - Arellano, J. AU - Qian, Y. PY - 2014 DA - 2014// TI - Patient preferences for treatments to delay bone metastases JO - Prostate VL - 74 ID - Hauber2014 ER - TY - BOOK AU - Ahmed, H. U. AU - Watson, V. AU - McCartan, N. PY - 2018 DA - 2018// TI - Evaluating the trade-offs men with localised prostate cancer make between the risks and benefits of treatments: the COMPARE study ID - Ahmed2018 ER - TY - JOUR AU - Scherr, K. A. AU - Fagerlin, A. AU - Hofer, T. PY - 2017 DA - 2017// TI - Physician recommendations trump patient preferences in prostate Cancer treatment decisions JO - Medical decision making : an international journal of the Society for Medical Decision Making VL - 37 ID - Scherr2017 ER - TY - JOUR AU - Bridges, J. F. AU - Hauber, A. B. AU - Marshall, D. PY - 2011 DA - 2011// TI - Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force JO - Value Health VL - 14 ID - Bridges2011 ER - TY - JOUR AU - Johnson, F. R. AU - Lancsar, E. AU - Marshall, D. PY - 2013 DA - 2013// TI - Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force JO - Value Health VL - 16 ID - Johnson2013 ER - TY - JOUR AU - Clark, M. D. AU - Determann, D. AU - Petrou, S. AU - Moro, D. AU - Bekker-Grob, E. W. PY - 2014 DA - 2014// TI - Discrete choice experiments in health economics: a review of the literature JO - PharmacoEconomics. VL - 32 ID - Clark2014 ER - TY - JOUR AU - Jenkins, V. AU - Fallowfield, L. AU - Edginton, T. AU - Payne, H. AU - Hamilton, E. PY - 2005 DA - 2005// TI - Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer JO - Curr Med Res Opin VL - 21 ID - Jenkins2005 ER - TY - STD TI - Kuhfeld WF. Marketing Research Methods in SAS: Experimental Design, Choice, Conjoint, and Graphical Techniques. http://support.sas.com/techsup/technote/mr2010.pdf. . UR - http://support.sas.com/techsup/technote/mr2010.pdf ID - ref24 ER - TY - STD TI - National Cancer Institute Division of Cancer Treatment and Diagnosis. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed June 11, 2018. UR - https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 ID - ref25 ER - TY - JOUR AU - Bekker-Grob, E. W. AU - Donkers, B. AU - Jonker, M. F. AU - Stolk, E. A. PY - 2015 DA - 2015// TI - Sample size requirements for discrete-choice experiments in healthcare: a practical guide JO - The Patient-Patient-Centered Outcomes Research VL - 8 ID - Bekker-Grob2015 ER - TY - JOUR AU - Hauber, A. B. AU - Gonzalez, J. M. AU - Groothuis-Oudshoorn, C. G. PY - 2016 DA - 2016// TI - Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force JO - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research VL - 19 ID - Hauber2016 ER - TY - JOUR AU - Sternberg, C. N. AU - Baskin-Bey, E. S. AU - Watson, M. AU - Worsfold, A. AU - Rider, A. AU - Tombal, B. PY - 2013 DA - 2013// TI - Treatment patterns and characteristics of European patients with castration-resistant prostate cancer JO - BMC Urol VL - 13 ID - Sternberg2013 ER - TY - STD TI - Bridges JF, Mohamed AF, Finnern HW, Woehl A, Hauber AB. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung cancer (Amsterdam, Netherlands). 2012;77(1):224–231. ID - ref29 ER - TY - JOUR AU - Wong, M. K. AU - Mohamed, A. F. AU - Hauber, A. B. PY - 2012 DA - 2012// TI - Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma JO - J Med Econ VL - 15 ID - Wong2012 ER - TY - JOUR AU - Freitas, H. M. AU - Ito, T. AU - Hadi, M. PY - 2019 DA - 2019// TI - Patient preferences for metastatic hormone-sensitive prostate Cancer treatments: a discrete choice experiment among men in three European countries JO - Adv Ther VL - 36 ID - Freitas2019 ER - TY - BOOK AU - Srinivas, S. AU - Mohamed, A. F. AU - Appukkuttan, S. PY - 2019 DA - 2019// TI - Patient and caregiver benefit-risk preferences for non-metastatic castration-resistant prostate Cancer treatment (nmCRPC) ID - Srinivas2019 ER -